The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma

Drugs

Volumn 61, Issue 9, 2001, Pages 1253-1274

  McCloskey, Eugene V ^a   Guest, Julian F ^b   Kanis, John A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID;

BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISCLERITIS; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VERTEBRA FRACTURE;

BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG TOLERANCE; HUMANS; HYPERCALCEMIA; MULTIPLE MYELOMA;

EID: 0034885581     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161090-00003     Document Type: Review

References (106)

1. Histomorphometric evidence for osteoclast mediated bone resorption in metastatic breast cancer
2. Bone disease in multiple myeloma
3. Bisphosphonates: Mechanisms of action
4. From polyphosphates to bisphosphonates and their role in bone and calcium metabolism
5. A randomised trial of the effect of clodronate on skeletal morbidity in myelomatosis
6. Effect of daily etidronate on the osteolysis of multiple myeloma
7. Randomised placebo controlled multicentre trial of clodraonte in multiple myeloma
8. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
9. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
10. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
11. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
12. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
13. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
14. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
15. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
16. Efficacy of pamidronate in breast cancer with bone metastases: A randomized, double-blind placebo-controlled multicenter study
17. Stimulation of calcium reabsorption observed in advanced breast cancer in patients with hypercalcemia and multiple bone metastases
18. Quantitative histology of myeloma-induced bone changes
19. 2MDP) on skeletal lesions in multiple myeloma
20. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption
21. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells
22. Interleukin-1 beta rather than lymphotoxin as a major bone resorbing activity in human multiple myeloma
23. Interactions between interleukin-6 and interleukin-1 in osteoclastic bone resorption in neonatal mouse calvaria
24. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma
25. Cellular regulatory mechanisms that may underlie the effects of corticosteroids on bone
26. Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption
27. Effects of glucocorticoids on osteoclast-activating factor
28. Does myeloma secrete an osteoblast inhibiting factor?
29. Myeloma affects both the growth and function of human osteoblast-like cells
30. Effects of secretory products of breast cancer cells on osteoblast-like cells
31. Secretory products of breast cancer cells affect human osteoblastic cells: Partial characterisation of active factors
32. A high incidence of vertebral fracture in women with breast cancer
33. Risk of osteoporotic fractures in women with breast cancer: A population band cohort study
34. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer
35. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study
36. Effect of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy premenopausal and postmenopausal women
37. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
38. Chemical castration induced by adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients
39. Influence of early age at menopause on vertebral bone mass
40. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
41. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antiestrogens
42. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen
43. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy
44. Bisphosphonates in multiple myeloma
45. Assessing vertebral fractures
46. The assessment of vertebral deformity: A method for use in population studies and clinical trials
47. Prevalence of vertebral deformity and concordance between definitions of fracture
48. The assessment of vertebral deformity
49. Economic impact of using clodronate in the management of patients with multiple myeloma
50. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
51. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
52. Oral bisphosphonates: A review of clinical use in patients with bone metastases
53. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
54. Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton
55. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma
56. A randomised, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain
57. A double blind cross-over trial of intravenous clondronate in metastatic bone pain
58. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: A multicentre study
59. Treatment of painful bone lesions and hypercalcaemia
60. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
61. Bisphosphonate residronate reduces metastatic human breast cancer burden in bone in nude mice
62. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix-metalloproteinase-2
63. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
64. Treatment of skeletal disease in breast cancer: A controlled clodronate trial
65. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
66. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
67. Prospective, controlled, non randomised study on prophylactic parenteral dichloremethylene bisphosphonate (clodronate) in multiple myeloma
68. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone
69. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma
70. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis
71. The Canadian American ticlopidine study (CATS) in thromboembolic stroke
72. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
73. British association of surgical oncology guidelines for the management of metastatic bone disease in the United Kingdom
74. Mineralisation defects with pamidronate therapy for Paget's disease
75. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma
76. Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion
77. Diphosphonates for osteolytic metastases
78. Rationale for the use of bisphosphonates in bone metastases
79. Effects of clodronate on immobilization bone loss
80. Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: A histomorphometric study
81. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hyperparathyroidism or malignant disease
82. Comparison of aminohydroxyprophylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia
83. Renal failure associated with intravenous diphosphonates
84. Clodronate as a cause of aminotransferase elevation
85. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment
86. Esophagitis associated with the use of alendronate
87. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
88. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy
89. Adverse effects of bisphosphonates: A comparative review
90. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone
91. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma
92. The acute-phase response after bisphosphonate administration
93. APD in Paget's disease of bone: Role of the mononuclear phagocyte system?
94. Side-effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone diseases
95. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations
96. Double blind, placebo controlled, dose response trial of oral clodronate in patients with bone metastases
97. Double blind placebo-controlled dose response trial of oral clodronate in patients with bone metastases
98. Effects of clodronate on vertebral fracture risk in established osteoporosis - A one year interim analysis
99. Clodronate kinetics and bioavailability
100. Pharmocokinetics of clodronate in patients with metastatic breast cancer
101. Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
102. Timing of food intake has a marked effect on the bioavailability of clodronate
103. Pooling of clodronate urinary excretion data: A new pharmacokinetic method to study drugs with highly variable gastrointestinal absorption
104. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial